CTRI/2012/07/002818已完成1 期
AN OPEN-LABEL, SINGLE-TREATMENT, SINGLE-PERIOD, SINGLE DOSE, CLINICAL PHASE 1 STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF LIVE RUBELLA VACCINE, (SINGLE DOSE VIAL FORMULATION) OF M/s CADILA HEALTHCARE LTD., INDIA IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS UNDER FASTING CONDITION - RBLSD 1001
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male subjects aged between 18 and 45 years (including both).
- •Subjectsâ?? weight within ï?±15% of the ideal height-weight chart of Life Insurance Corporation of India for non-medical cases.
- •Ability to communicate effectively with study personnel.
- •Willingness to adhere to the protocol requirements.
- •Be able to give consent for participation in the trial.
- •Normal health as determined by personal medical history, clinical examination and laboratory examinations data during screening (within the clinically acceptable range).
排除标准
- •History of anaphylaxis or serious reactions to vaccines, egg proteins, gelatin or gelatin containing products.
- •Subjects who are taking immunostimulant therapy (e.g. interferons) or immunosuppressant medications (e.g. corticosteroids, cytotoxic drugs or antimetabolites, etc.).
- •Subjects who are known to be suffering from diseases which can affect immune competence e.g. diabetes, immunodeficiency disorders or known to be HIV positive.
- •Subjects who have received immunoglobulins parenterally during the preceding 3 months.
- •Subjects who have received any vaccine in the preceding 6 months.
- •History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement.
- •History or presence of significant alcoholism or drug abuse within the past one-year.
- •History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco products.
- •Difficulty with donating blood.
- •Blood pressure less than 100/60 mm Hg or more than 140/90 mm Hg.
- •Pulse less than 60/minute or more than 110/minute.
- •Any ECG abnormalities.
- •Any clinically significant abnormal laboratory values during screening.
- •Any clinically significant chest X-Ray findings during screening.
- •Major illness during 3 months before the screening period
- •Subjects who have participated in drug research studies within past 3 months.
- •Subjects who have donated one unit (350ml) of blood in the past 3 months.
研究者
相似试验
进行中（未招募）
1 期
A CLINICAL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF INACTIVATED HEPATITIS A VACCINE (ADSORBED) I.P. OF M/s CADILA HEALTHCARE LTD., INDIA IN HEALTHY, ADULT HUMAN SUBJECTSCTRI/2020/01/022797Cadila Healthcare Ltd
已完成
1 期
PHASE 1 STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF INACTIVATED TETRAVALENT INFLUENZA VACCINE (SPLIT VIRION)CTRI/2014/08/004857Cadila Healthcare Limited24
已完成
1 期
TO ASSESS THE SAFETY AND TOLERABILITY OF LIVE MEASLES AND RUBELLA VACCINE IN HEALTHY, ADULT, MALE, HUMAN SUBJECTSCTRI/2012/08/002874Cadila Healthcare Limited24
已完成
1 期
TO ASSESS THE SAFETY AND TOLERABILITY OF LIVE MEASLES, MUMPS AND RUBELLA VACCINE IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS UNDER FASTING CONDITIONS.CTRI/2012/08/002875Cadila Healthcare Limited24
已完成
1 期
TO ASSESS THE SAFETY AND TOLERABILITY OF LIVE MEASLES AND RUBELLA VACCINE INDIA IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS UNDER FASTING CONDITIONS.CTRI/2012/07/002841Cadila Healthcare Limited24